Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: SAR566658 (ACT14884)
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 23
- Registration Number
- NCT02984683
- Locations
- 🇳🇱
Investigational Site Number 5280002, Rotterdam, Netherlands
🇧🇪Investigational Site Number 0560001, Leuven, Belgium
🇨🇿Investigational Site Number 2030002, Praha 2, Czechia
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: placebo
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 35
- Registration Number
- NCT02979015
- Locations
- 🇨🇳
Investigational Site Number 156001, Beijing, China
A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT02977533
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 296
- Registration Number
- NCT02973321
- Locations
- 🇷🇺
Investigational Site Number 6430003, Saratov, Russian Federation
🇷🇺Investigational Site Number 6430001, St-Petersburg, Russian Federation
🇷🇺Investigational Site Number 6430005, Voronezh, Russian Federation
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: insulin glargine (U100)Drug: NPH insulin
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 609
- Registration Number
- NCT02967211
- Locations
- 🇮🇹
Investigational Site Number 380007, Forlì, Italy
🇮🇹Investigational Site Number 380012, Milano, Italy
🇮🇹Investigational Site Number 380026, Padova, Italy
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: insulin glargine (U100)Drug: NPH insulin
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 705
- Registration Number
- NCT02967224
- Locations
- 🇮🇪
Investigational Site Number 372003, Dublin 4, Ireland
🇮🇪Investigational Site Number 327002, Dublin 7, Ireland
🇫🇷Investigational Site Number 250045, Montpellier, France
Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 136
- Registration Number
- NCT02967237
- Locations
- 🇫🇷
Investigational Site Number 250062, Bagnols-sur-Cèze, France
🇫🇷Investigational Site Number 250081, BETHUNE Cedex, France
🇫🇷Investigational Site Number 250093, Bar le Duc, France
A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: sulfonylureaDrug: meglitinidesDrug: thiazolidinedionesDrug: GLP1 Receptor AgonistDrug: Dipeptidyl peptidase-IV (DPP-IV) inhibitorsDrug: Sodium-glucose transport-2 (SGLT-2) inhibitors
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 112
- Registration Number
- NCT02954692
Evaluation of Dupilumab in Children With Uncontrolled Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 408
- Registration Number
- NCT02948959
- Locations
- 🇺🇸
Investigational Site Number 840012, Tucson, Arizona, United States
🇺🇸Investigational Site Number 840001, Rolling Hills Estates, California, United States
🇺🇸Investigational Site Number 840016, Ann Arbor, Michigan, United States
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 184
- Registration Number
- NCT02941367
- Locations
- 🇮🇳
Investigational Site Number 356005, Ahmedabad, India
🇮🇳Investigational Site Number 356002, Bangalore, India
🇮🇳Investigational Site Number 356008, Bangalore, India